These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32861285)

  • 1. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance.
    Ladetto M; Tavarozzi R; Pott C
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):887-901. PubMed ID: 32861285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
    Wu S; Blombery P; Westerman D; Tam CS
    Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
    Hoster E; Pott C
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.
    Kumar A; Bantilan KS; Jacob AP; Park A; Schoninger SF; Sauter C; Ulaner GA; Casulo C; Faham M; Kong KA; Grewal RK; Gerecitano J; Hamilton A; Hamlin P; Matasar M; Moskowitz CH; Noy A; Palomba ML; Portlock CS; Younes A; Willis T; Zelenetz AD
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):230-237.e12. PubMed ID: 33558202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
    Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.
    Chovancová J; Bernard T; Stehlíková O; Šálek D; Janíková A; Mayer J; Doubek M
    Cytometry B Clin Cytom; 2015 Mar; 88(2):92-100. PubMed ID: 25586981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
    Wu X; Lu H; Pang T; Li X; Luo H; Tan H; Liu S
    Leuk Res; 2021 Sep; 108():106605. PubMed ID: 34090063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
    Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
    Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
    Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
    Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
    Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance.
    Pott C
    Semin Hematol; 2011 Jul; 48(3):172-84. PubMed ID: 21782059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of SOX11 in mantle cell lymphoma.
    Lu TX; Li JY; Xu W
    Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of mantle cell lymphoma in the primary setting.
    Tang C; Kuruvilla J
    Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
    [No Abstract]   [Full Text] [Related]  

  • 18. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
    Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
    Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
    Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
    Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the assessment of minimal residual disease in mantle cell lymphoma.
    Jung D; Jain P; Yao Y; Wang M
    J Hematol Oncol; 2020 Sep; 13(1):127. PubMed ID: 32972438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.